Vertical distribution changes with time. by Xuegang Mao (599968)

Subjects:

Magnetic field setups in zero field (a) and vertically alternating field (b). by Xuegang Mao (599968)

Subjects:

Procedures of sampling and measurements. by Xuegang Mao (599968)

Subjects:

Vertical distributions in the three field settings. by Xuegang Mao (599968)

Subjects:

This table contains all experimental data underlying Figs 3–7. by Xuegang Mao (599968)

Subjects:

Statistical evaluation of cerebral autoregulation indices at different time points during the experiment: baseline, last LBNP/LBPP level (LBNP: first 10 seconds), presyncope (5 sec... by Marcus Thudium (6441863)

Fig S1. Top 50 hub genes identified in (A) module 3 (M3) and (B) module 4 (M4) based on the degree method implemented in the Cytoscape plugin cytoHubba for ranking nodes in a network by their network features.... by Gaurab Bhattarai (18542266)

Supplementary File S2 provides the full R Markdown script used for data cleaning, statistical analyses, and figure generation related to mass, evaporation, impedance, and I–V curve... by Juan P. Hernández (22216133)

PT₅₀ values of GO and GO-GA NPs against <i>Callosobruchus maculatus.</i> by Huda H. Elbehery (22492996)

Effects of 1466 on capsid and pgRNA encapsidation compared to known CAM-A and CAM-E inhibitors. by Daniel P. Bradley (10306893)

Fig 5 - by Cristoforo Simonetto (563944)

Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial by Michel Mandro (2637532)

“…<div><p>Introduction</p><p>Recent findings from onchocerciasis-endemic foci uphold that increasing ivermectin coverage reduces the epilepsy incidence, and anecdotal evidence suggests seizure frequency reduction in persons with onchocerciasis-associated epilepsy, when treated with ivermectin. We conducted a randomized clinical trial to assess whether ivermectin treatment decreases seizure frequency.…”

S3 File - by Andrei Rajkovic (10965915)

2‑Aminobenzoxazole Derivatives as Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spinster Homolog 2 (Spns2) by Ariel L. Burgio (15069256)

“…To develop more potent compounds, we initiated a structure–activity relationship study that identified 2-aminobenzoxazole as a viable scaffold. …”

Kinematic analyses including finite helical axes of drop jump landings demonstrate decreased knee control long after anterior cruciate ligament injury - Fig 4 by Helena Grip (7610468)

Density plots of normalised consumer final power (PC) for the six example networks, shown over decreasing ratios of mean consumer to mean resource potential, . by Natalie Davis (8556036)

Identification of metabolites with cell type-specific-dynamics reveals the amino acid class as highly conserved in hiPSC and hNSC and that most of the cell type-specific amino acid... by João Vasconcelos e Sá (8721594)

Impact of SARS‐CoV‐2 infection on T, B and NK cell numbers in severe and moderate patients (* P< 0.05, ** P< 0.01). by Sam Alahyari (12645313)

DataSheet5_Novel Starting Points for Human Glycolate Oxidase Inhibitors, Revealed by Crystallography-Based Fragment Screening.ZIP by Sabrina R. Mackinnon (12496324)

An increase in MOI decreases neuronal dendrite numbers. by Emily Z. Tabaie (16630841)